{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T17:12:59Z","timestamp":1712077979210},"reference-count":12,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2011,5,31]],"date-time":"2011-05-31T00:00:00Z","timestamp":1306800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:italic>Background:<\/jats:italic> The basis of induction therapy for psoriasis in Germany is the S3\u2010guideline which for moderate to severe psoriasis recommends the systemic agents fumaric acid esters, methotrexate, cyclosporine and the biologicals infliximab, etanercept, adalimumab and ustekinumab. Systemic glucocorticos\u2010teroids (GCS) are not proposed.<\/jats:p><jats:p><jats:italic>Question:<\/jats:italic> To what extend are systemic glucocorticosteroids prescribed in psoriasis therapy?<\/jats:p><jats:p><jats:italic>Methods:<\/jats:italic> The database of a German nationwide statutory health insurance 2007 was analyzed. Prescriptions of systemic glucocorticosteroids were identified by ATC\u2010encoding. Psoriasis patients with comorbidities requiring systemic glucocorticosteroid medication were analyzed separately.<\/jats:p><jats:p><jats:italic>Results:<\/jats:italic> Among 1 423 308 continuously insured patients in 2007 n = 34 728 (2.4 %) were patients with psoriasis. The most prescribed systemic agents were corticosteroids (2774 patients), followed by methotrexate (853), fumaric acid esters (342), retinoids (110) and cyclosporine A (105). Even after excluding patients with psoriatic arthritis, systemic corticosteroids were still the most often prescribed systemic drugs. The average number of DDD (Defined Daily Doses) per insured patient was 120 (general practitioners), 141 (internists) and 68 (dermatologists). These results were confirmed by a control analysis with IMS data.<\/jats:p><jats:p><jats:italic>Conclusions:<\/jats:italic> In Germany, psoriasis is often treated with systemic corticosteroids though these are not recommended by the S3\u2010guideline. General practitioners and internists are the main prescribers.<\/jats:p>","DOI":"10.1111\/j.1610-0387.2011.07713.x","type":"journal-article","created":{"date-parts":[[2011,5,31]],"date-time":"2011-05-31T12:56:49Z","timestamp":1306846609000},"page":"833-838","source":"Crossref","is-referenced-by-count":14,"title":["Systemic treatment with corticosteroids in psoriasis\u2013health care provision far beyond the S3\u2010guidelines"],"prefix":"10.1111","volume":"9","author":[{"given":"Matthias","family":"Augustin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian","family":"Reich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Glaeske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Radtke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,5,31]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"S1\u2013 S126","DOI":"10.1111\/j.1610-0387.2006.06172.x","article-title":"S3\u2010Leitli\u2010nie zur Therapie der Psoriasis vulgaris","volume":"4","author":"Nast A","year":"2006","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_6_3_2","unstructured":"NastA BoehnckeWH MrowietzU OckenfelsHM PhilippS ReichK RosenbachT SammainA SchlaegerM SebastianM SterryW StreitV AugustinM ErdmannR KlausJ KozalJ MullerS OrzechowskiHJ RosumeckS Schmid\u2010OttG Weber\u2010schockT RzanyB.S3\u2010Leitlinie zur Therapie der Psoriasis vulgaris.http:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/013\u2010\u2010001l_S3_Psoriasis_vulgaris_Therapie_01.pdf"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.03.027"},{"key":"e_1_2_6_5_2","first-page":"2121","article-title":"Werkgroep Psoriasis van de Nederlandse Vereniging voor Dermato\u2010logie en Venereologie. [The practice guideline \u2018Photo(chemo)therapy and systemic therapy in severe chronic plaque\u2010psoriasis\u2019]","volume":"148","author":"Spuls PI","year":"2004","journal-title":"Ned Tijdschr Geneeskd"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03389.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000119415"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2010.07358.x"},{"key":"e_1_2_6_9_2","volume-title":"Methodik der ATC\u2010Klassifikation und DDD\u2010Festlegung f\u00fcr den deutschen Arzneimittelmarkt, Herausgegeben vom WIdO","author":"Fricke U","year":"2007"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0770"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000136656"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2008.06967_supp.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"640\u2013 646","DOI":"10.1111\/j.1610-0387.2008.06807.x","article-title":"Versorgungsqualit\u00e4t der Psoriasis vulgaris in Deutschland\u2013Ergebnisse der Nationalen Versorgungs\u2010studie PsoHealth 2007 [Quality of psoriasis care in Germany \u2013 results of the national study PsoHealth 2007]","volume":"6","author":"Augustin M","year":"2008","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1610-0387.2011.07713.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1610-0387.2011.07713.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T11:13:09Z","timestamp":1697454789000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1610-0387.2011.07713.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,31]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1111\/j.1610-0387.2011.07713.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1610-0387.2011.07713.x","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,31]]}}}